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Oxidative stress markers may be novel factors contributing to cardiovascular 
(CVD) risk.  The purpose of this study was to examine the effects of long-term 
exercise, age, and their interaction on the plasma levels of the oxidative stress 
markers oxidized LDL (ox-LDL), nitrotyrosine, and myeloperoxidase (MPO), and to 
investigate whether these levels correlated with plasma NOx levels.  Older (62 ± 2 yr) 
active (n=12) men who had exercised regularly for over 30 years and young (25 ± 4 
yr) active (n=7) men who had exercised regularly for over 3 years were matched to 
older (n=11) and young (n=8) inactive males.  Young subjects showed lower plasma 
nitrotyrosine levels than older subjects (P = 0.047).  Young inactive subjects had 
higher ox-LDL levels than either the young active (P = 0.042) or the older active (P = 
0.041) subjects.  In addition, plasma oxidative stress levels, particularly ox-LDL, 
were correlated with various conventional CVD risk factors, and in older subjects 
were associated with Framingham risk score (r = 0.49, P = 0.015).  The study found 
no relationships between plasma markers of oxidative stress and plasma NOx levels.  
The findings suggest that a sedentary lifestyle may be associated with higher ox-LDL 
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Blood lipid profiles, blood pressure, smoking status, and other conventional 
risk factors have long been considered in estimating an individual’s cardiovascular 
disease (CVD) risk.  However, in the late 1990s, evidence suggested that these 
conventional CVD risk factors might only be explaining half of CVD cases (16).  In 
addition, only about 60% of the reduction in CVD risk through regular exercise could 
be attributed to training-induced improvements in conventional CVD risk factors 
(44).  Thus, the search began for novel risk factors that might help provide a more 
complete picture of a person’s CVD risk.  Among the most promising novel risk 
factors recently linked to CVD are oxidative stress markers. 
Reactive oxygen species (ROS) are produced as intermediates in a variety of 
metabolic reactions in the body.  In healthy tissues, any increase in ROS is 
accompanied by an increase in antioxidant capacity, preventing the buildup of excess 
ROS.  When this delicate balance is disrupted and excess ROS results, the body 
experiences “oxidative stress” as the highly reactive ROS interact with lipids, 
proteins, and nucleic acids to cause cellular damage.  In addition to cell damage, 
research suggests that oxidative stress can contribute to the development of various 
pathologies including aging, dementia, and atherosclerosis (47). 
 The proposed role of oxidative stress in atherosclerosis has been termed the 
oxidative modification hypothesis (64).  According to this hypothesis, oxidized 




wall and promoting plaque formation and by interacting with inflammatory and 
endothelial dysfunction pathways which negatively affect vascular function.  Because 
of their involvement in the atherosclerotic disease process, various biomarkers of 
oxidative stress may have predictive value for CVD.  Particularly attractive to 
primary care practitioners are potential systemic markers of oxidative stress that 
could be measured in a minimally invasive manner, such as plasma levels of oxidized 
LDL (ox-LDL), nitrotyrosine, and myeloperoxidase (MPO). 
Early research has linked plasma levels of ox-LDL, nitrotyrosine, and MPO to 
CVD (21, 32, 61).  Ox-LDL is linked to atherosclerosis because unlike native LDL, 
ox-LDL migrates into the subendothelial space, is taken up by macrophages, and 
promotes foam cell formation (51).  Ox-LDL also seems to promote endothelial 
dysfunction, vascular remodeling, plaque rupture, and thrombosis (64).  Plasma levels 
of ox-LDL have been shown to be predictive of future CVD events (39). 
Serving as a marker of protein nitration, nitrotyrosine has been associated with 
inflammation and endothelial dysfunction (7).  Elevated nitrotyrosine levels have 
been found in atherosclerotic lesions, and increased nitrotyrosine levels are associated 
with various CV disease states (63). 
The enzyme MPO plays a role in many of the oxidative modifications 
associated with atherosclerosis and the resulting endothelial dysfunction by 
catalyzing the formation of several oxidants (48).  Elevated plasma levels of MPO 
have been associated with CVD (71). 
The role of physical activity in reducing CVD risk by improving conventional 




less is known about the effect of long-term physical activity and the interaction of 
exercise training and age on many of the novel risk factors.  Previous studies indicate 
that short-term exercise training interventions reduce plasma levels of oxidative stress 
(45), but studies have not investigated the effects of long-term exercise training or age 
on oxidative stress markers.  In addition, while endothelial dysfunction resulting from 
elevated oxidative stress levels has been implicated in CVD (64), no studies have 
examined whether the effects of training or age on oxidative stress levels are related 
to changes in endothelial health or NO bioavailability. 
The present study is an important initial step in understanding oxidative stress 
as an emerging CVD risk factor because it seeks to examine how long-term physical 
activity and age may affect plasma levels of ox-LDL, nitrotyrosine, and MPO.  The 
findings could justify further research into the changes in oxidative stress levels 
induced by short-term exercise training interventions, the mechanisms underlying 
these modifications, and their clinical consequences.  In addition, the study attempts 
to link the effects of training and age on oxidative stress levels to changes in NO 
bioavailability by measuring plasma levels of the final products of nitric oxide (NO) 
metabolism, collectively called NOx.  The finding of a negative relationship between 
plasma levels of NOx and plasma levels of ox-LDL, nitrotyrosine, or MPO would 
lend support to the theory that elevations in oxidative stress levels increase CVD risk 
by reducing NO bioavailability, which in turn causes endothelial dysfunction. 
Specific Aims and Hypotheses 
The first aim of this study is to examine the effects of long-term exercise 




MPO, and NOx.  It is hypothesized that plasma levels of ox-LDL, nitrotyrosine, and 
MPO will be lower, and NOx levels higher, in active individuals compared to their 
inactive peers.  In addition, plasma levels of ox-LDL, nitrotyrosine, and MPO will be 
higher, and NOx levels lower, in older groups compared to their corresponding young 
group. 
 The second aim of the study is to determine whether NOx levels are correlated 
with the plasma levels of ox-LDL, nitrotyrosine, and MPO.  It is hypothesized that 








To study the impact of long-term exercise training and age on oxidative stress, 
the study used a cross-sectional approach with four groups and 38 total subjects.  All 
subjects were originally recruited, screened, and tested as described in three previous 
studies (26, 27, 70).  All participants were men who provided written informed 
consent as part of their participation in the Long Term Exercise and Vascular Health 
Study.  In addition, all procedures were approved by the Institutional Review Board 
at the University of Maryland. 
Subjects 
Older (62 ± 2 yr) active (n=12) men who had performed moderate- to high-
intensity endurance exercise for over four hours per week for over thirty years were 
BMI- and age-matched to inactive (n=11) males.  The older subjects were from 55 to 
77 years of age. 
Young (25 ± 4 yr) active (n=7) men who had performed moderate- to high-
intensity endurance exercise for over four hours per week for over three years were 
matched on the basis of BMI, age, body composition, and conventional CV risk factor 
profile to inactive (n=8) males.  The young subjects were from 18 to 30 years of age. 
All subjects were healthy, nonsmoking, and currently free of and with no 




hypertension, or if they were taking cholesterol-lowering, antihypertensive, or 
antihyperglycemic agents.   
The active subjects were located with the help of recruitment flyers posted in 
local running and cycling stores, on their websites, and in their newsletters.  In 
addition, Department of Kinesiology faculty members who participated in local 
running clubs talked with fellow members who met the subject qualifications, and 
other Department of Kinesiology studies with subjects qualified for this study were 
approached. 
 The inactive groups consisted of lean, healthy individuals who for at least five 
years had participated in physical activity less than twice per week for less than 20 
minutes per session with a sedentary occupation or retired.  The inactive subjects 
were recruited as matches for the active group on an individual basis.  To be 
considered a match, the inactive male had to be of the same ethnicity, have an age 
within five years, and a BMI within 1 kg/m2 of the active male.  Many of the inactive 
subjects were recruited from subject pools of other studies going on in the 
Department of Kinesiology. 
Outcomes 
Venous blood samples were drawn and stored so that the plasma levels of ox-
LDL, nitrotyrosine, MPO, and NOx could be compared in the four groups of men: 
older active, young active, older inactive, and young inactive.  In addition to blood 





The study was completed in two visits, with VO2 max and body composition 
testing done on the first visit.  On the second visit, venous blood samples were drawn 
in the morning following a 12- to 16-hour fast and stored at -80°C. 
Prior to any testing in older subjects, a physician performed a physical 
examination to screen for CVD and to identify contraindications to exercise testing.  
All testing occurred the morning after an overnight fast.  All subjects had avoided 
alcohol, vitamins, caffeine, and medications for 24 hours before testing.  For active 
subjects the visits occurred 16 to 24 hours after one of the subject’s usual physical 
activity sessions. 
Instrumentation 
Maximal Graded Exercise Testing 
 
Participants performed a maximal treadmill exercise test to screen for CVD 
and assess VO2 max.  A constant-speed treadmill protocol was used with the grade 
increasing 2% with each successive 2 minute stage until exhaustion.  The treadmill 
speed was selected by the investigator based on subject experience, typical run/walk 
speed, and heart rate such that VO2 max would be achieved in 6-12 minutes.  In the 
older subjects, ECG was used during the test to measure heart rate.  Heart rate in the 
young subjects was measured during testing with heart rate monitors (Polar Electro, 
Woodbury, NY).  Open-circuit spirometry was used to measure maximal oxygen 
consumption, with the subject’s pulmonary ventilation measured and fractions of 




automated indirect calorimetry system (Oxycon Pro, Viasys).  By comparing the 
amount of oxygen inspired to the amount expired, the amount of oxygen consumed 
was calculated.  For the older subjects, a valid VO2 max required that at least three of 
the following criteria were met: a respiratory exchange ratio ≥ 1.15, a heart rate that 
was equivalent to the age-predicted max, a plateau in oxygen uptake with increases in 
workload, or the subject indicated exhaustion.  For the young subjects, a valid VO2 
max required a plateau in oxygen uptake with increasing workload and at least two of 
the following criteria were met: a respiratory exchange ratio ≥ 1.10, a rating of 
perceived exertion ≥ 19, or a peak heart rate within ten beats of the age-predicted 
max. 
Body Composition Testing 
 
For all subjects, height, weight, and blood pressure were measured and body 
mass index (BMI) was calculated.  For older subjects, body fatness was assessed with 
dual x-ray absorptiometry (Hologic).  In young subjects, body fatness was estimated 
using the seven-site skinfold procedure (25). 
Blood Chemistry Testing 
 
 Blood samples were sent to Quest Diagnostics for analysis.  The following 
levels were measured: glucose, triglycerides, total cholesterol, HDL cholesterol, and 
LDL cholesterol.  In addition, the ratios of total cholesterol to HDL cholesterol and 
ox-LDL to LDL cholesterol were calculated.  Finally, to calculate the subject’s 
overall CVD risk, the conventional CVD risk factors that were measured were 




Plasma Ox-LDL Measurement 
Plasma ox-LDL levels in the older subjects were measured previously with a 
commercially-available competitive Enzyme-Linked Immunosorbent Assay (ELISA) 
kit (Mercodia) (70).  The present study used the same assay to measure ox-LDL in the 
young subjects.  The ELISA was performed in accordance with the manufacturer’s 
directions for use for product number 10-1158-01, which required a dilution of 
plasma samples with the provided sample buffer.  With both the assay previously 
performed on older subject samples and the assay performed in the present study on 
young subject samples, two-level control samples (Mercodia) of a known ox-LDL 
concentration were assayed.  These controls confirmed that the procedure was able to 
detect a positive result. 
In the competitive ELISA kit, ox-LDL in the sample competes with a fixed 
amount of ox-LDL in the well plate for the binding of the mouse monoclonal 
antibody 4E6.  The antibody is able to bind the ox-LDL molecules because during 
lipoprotein oxidation aldehydes are substituted for lysine residues in the 
apolipoprotein B-100 region of the molecule, resulting in the generation of a new 
conformational epitope (20).  The 4E6 antibody has been used in several previous 
studies to measure ox-LDL levels, including a study that found an increase in ox-LDL 
levels in patients with coronary artery disease (20, 21, 22, 39, 50). 
Previously, all samples in the older group were analyzed in a single assay, and 
in the present study all samples from young subjects were analyzed in a single assay.  
Thus, within each group the interassay variability was minimized.  However, when 




Previous studies using this ox-LDL assay have cited an interassay variability of 12%, 
indicating that the measurements are reliable (20).  Samples from older and young 
subjects were run in duplicate to minimize the intra-assay variability and the results 
were averaged.  For the older subjects, the intra-assay coefficient of variation was 
6.8% (70).  For the young subjects analyzed in the present study, the average intra-
assay coefficient of variation for the competitive ox-LDL assay was 9.58%. 
Plasma Nitrotyrosine Measurement 
 Nitrotyrosine was measured using a commercially-available ELISA kit (Cell 
Sciences).  The kit is a solid-phase ELISA based on the sandwich principle that 
detects nitrotyrosine-containing proteins in plasma.  To ensure accurate measurement, 
the plasma samples were diluted with the provided dilution buffer per manufacturer’s 
instructions for product number HK501.  As a part of the constructed standard curve, 
two wells were filled with dilution buffer only, and they served as negative controls 
for the assay.  
 Interassay variability was controlled by running all samples in a single run.  In 
addition, all samples were analyzed in duplicate, minimizing intra-assay variability, 
and the results were averaged.  The average intra-assay coefficient of variation for the 
nitrotyrosine assay was 9.1%. 
Plasma MPO Measurement 
MPO was measured with the Human MPO ELISA kit (Cell Sciences).  The 
assay is a solid-phase ELISA based on the sandwich principle that measures the 
amount of MPO in plasma.  To ensure accurate measurement, the plasma samples 




product number HK324.  As a part of the constructed standard curve, two wells were 
filled with dilution buffer only, and they served as negative controls for the assay. 
All samples were analyzed in one run to control interassay variation.  In 
addition, all samples were run in duplicate to minimize intra-assay variability and the 
results were averaged.  The average intra-assay coefficient of variation for the MPO 
assay was 5.0%. 
Plasma NOx Measurement 
The short half-life of NO makes it impossible to accurately measure NO levels 
directly.  However, the final products of NO metabolism, nitrite and nitrate, can be 
measured in plasma.  Collectively called NOx, the sum of nitrite and nitrate 
concentrations serve as an indicator of NO production (53). 
In the present study, plasma NOx levels were measured using a Nitrate/Nitrite 
Colorimetric Assay Kit (Cayman Chemical Company).  The kit provided an accurate 
and convenient way to perform a modified version of the Griess assay.  First, nitrate 
was converted to nitrite using nitrate reductase.  Then the addition of the Griess 
Reagents converted nitrite into a purple azo compound.  The azo compound is 
capable of selectively absorbing particular wavelengths of light.  Using a plate reader 
to measure the optical density of each sample at 541 nm, the absorbed light can be 
quantified.  To do this, a standard curve was constructed by plotting the absorbance 
measured for known quantities of nitrate.  As a part of the constructed standard curve, 
two wells were filled with assay buffer only, and they served as negative controls for 




sample absorbance and plotting the result on the constructed standard curve, the total 
concentration of nitrate and nitrite was determined. 
As outlined in the manufacturer’s instructions for product number 780001, the 
plasma samples were diluted with the provided assay buffer.  All samples were run in 
triplicate to minimize intra-assay variability and the results were averaged.  Although 
two separate plates were used, inter-assay variation was minimized by creating a 
standard curve for each plate.  The average intra-assay coefficient of variation for the 
two plates was 7.7%, and the inter-assay coefficient of variation was 13.2%. 
Statistical Analysis 
A two-way ANOVA was done with SPSS software to examine the main 
effects of long-term exercise training and age, along with the interaction effect of 
physical activity and age, on the plasma levels of ox-LDL, nitrotyrosine, MPO, and 
NOx.  Multiple comparisons between study groups were analyzed with Fisher’s Least 
Significant Difference method.  One-sided p-values are presented for tests of a priori 
directional hypotheses, unless group means were opposite the direction hypothesized, 
in which case two-tailed p-values are presented.  Regression analysis was performed 
to determine whether there were any significant relationships between levels of NOx 
and levels of the selected oxidative stress markers.  In addition, Pearson correlation 
coefficients were used to assess relationships among study variables.  An α value of 








Active and inactive subjects were successfully matched for age and BMI 
(Table 1).  However, as expected, active subjects had significantly higher VO2 max 
values.  In addition, older active subjects had significantly lower body fat and 
significantly better blood chemistry profiles than older inactive subjects. 
Ox-LDL 
Multiple comparisons revealed that the young inactive group had significantly 
higher ox-LDL levels than either the young active (P = 0.042) or older active (P = 
0.042) groups (Figure 1).  There were no significant (P < 0.05) main effects of age or 
long-term exercise training on plasma ox-LDL levels, and no significant interaction 
effect (Figures 2A and 2B).  However, there was a trend (P = 0.05) suggesting that 
long-term exercise training is associated with lower ox-LDL levels (Figure 2B).  An 
examination of the relationships between plasma ox-LDL levels and conventional 
CVD risk factors found significant positive correlations between ox-LDL levels and 
LDL cholesterol (r = 0.325, P = 0.046), ox-LDL to LDL ratio (r = 0.361, P = 0.026), 
and total cholesterol to HDL ratio (r = 0.483, P = 0.002) across all study subjects 
(Figures 3A, 3B, 3C).  Also significant was the inverse correlation (r = - 0.467, P = 
0.003) between plasma ox-LDL and HDL cholesterol (Figure 3D).  The plasma ox-
LDL levels reported here are consistent with the values found in other studies in the 






 Multiple comparisons showed no between-group differences in plasma 
nitrotyrosine levels (Figure 4).  There was a significant main effect of age on plasma 
nitrotyrosine (P = 0.047, one-tailed), with older individuals having significantly 
higher levels (Figure 5A).  There was no significant interaction effect between age 
and long-term exercise training and no significant main effect of long-term exercise 
training on plasma nitrotyrosine levels (Figure 5B).  In addition, across all subjects 
there was a significant positive correlation (r = 0.429, P = 0.008) between plasma 
nitrotyrosine levels and systolic blood pressure (Figure 6).  The circulating levels of 
nitrotyrosine found in other studies vary widely, but the values reported here fall 
within the range of values reported in the literature (15, 54).   
MPO 
 Between-group analyses showed that the young active group had significantly 
higher plasma MPO levels (P = 0.012) compared to the older inactive group (Figure 
7).  However, there were no significant main effects of age or long-term exercise 
training on plasma MPO levels and no significant interaction effect (Figures 8A and 
8B).  In addition, there was a significant inverse correlation (r = - 0.348, P = 0.035) 
across all subjects between plasma MPO levels and triglyceride levels (Figure 9).  
The numbers reported here for plasma MPO concentrations are consistent with other 





Tests of multiple comparisons revealed that the older inactive group had 
significantly higher plasma NOx levels than either the older active (P = 0.021) or the 
young active (P = 0.02) groups (Figure 10).  However, there were no significant main 
effects of age or long-term exercise training on plasma NOx levels and no significant 
interaction effect (Figures 11A and 11B).  In addition, there were no significant 
correlations between plasma NOx and any of the other outcome variables, ox-LDL, 
nitrotyrosine, or MPO.  Interestingly, a significant inverse correlation (r = - 0.357, P = 
0.03) was found between VO2 max and plasma NOx levels across all study subjects 
(Figure 12A).  Also observed across all subjects was a significant positive correlation 
(r = 0.355, P = 0.042) between plasma NOx levels and the ratio of total cholesterol to 
HDL cholesterol (Figure 12B).  In addition, the NOx values found in the present 
study are comparable to other values reported in the literature (5).   
Within-Age Group Correlation Analysis 
 In addition to assessing correlations across all subjects, the study examined 
relationships between outcome variables and conventional CVD risk factors within 
age groups.  These analyses were justified given the lack of any statistically 
significant age × activity interaction effects on the study’s main outcomes.  If a 
significant interaction effect had been uncovered, these within-age group analyses 
would not have been appropriate.  In young subjects, plasma ox-LDL levels were 
negatively correlated (P < 0.05) with VO2 max (Figure 13).  In older subjects, levels 
of ox-LDL were positively associated (P < 0.05) with several blood chemistry 




a positive relationship (P < 0.05) between plasma ox-LDL levels and the Framingham 
risk score and risk percentage was observed in older subjects (Figure 15A and 15B).  
Finally, many of the significant relationships in the combined group that were 
discussed above were also found within age groups.  Because those relationships 
were already presented, the corresponding within-age group correlations are not 
shown. 
Within-Activity Level Group Correlation Analysis 
 When subjects were divided by activity level, plasma MPO levels were 
positively correlated (P < 0.05) with the ox-LDL to LDL cholesterol ratio in inactive 
subjects (Figure 16).  In addition, several of the significant associations already 
shown for the combined group were also found within-activity level groups, but they 




Table 1. Subject Characteristics 
 Young Older 
Characteristic Active (n=7) Inactive (n=8) Active (n=12) Inactive (n=11) 
Age, yr 25 ± 4 25 ± 3 62 ± 6 64 ± 5 
Height, m 1.83 ± 0.1 1.81 ± 0.04 1.76 ± 0.07 1.75 ± 0.07 
Weight, kg 81.1 ± 12.5 77.9 ± 17.2 70.7 ± 10.6 74.7 ± 8.0 
BMI, kg/m2 24.4 ± 3.9 23.6 ± 4.4 22.9 ± 2.6 24.3 ± 2.1 
Body Fat, % 14.3 ± 5.8 14.8 ± 6.7 18.0 ± 4.5 23.5 ± 5.9 * 
Glucose, mg/dL 86 ± 7 81 ± 7 94 ± 7 101 ± 9 
TG, mg/dL 69 ± 19 81 ± 31 66 ± 29 103 ± 45 * 
TC, mg/dL 146 ± 21 147 ± 25 199 ± 31 194 ± 35 
HDL, mg/dL 53 ± 5 49 ± 11 71 ± 12 51 ± 15 * 
LDL, mg/dL 79 ± 21 82 ± 22 115 ± 29 123 ± 38 
TC/HDL 2.8 ± 0.6 3.1 ± 0.8 2.9 ± 0.7 4.2 ± 1.6 * 
SBP, mmHg 118 ± 6 121 ± 5 126 ± 14 133 ± 10 
DBP, mmHg 78 ± 5 79 ± 6 81 ± 7 86 ± 6 
VO2 max, mL/kg/min 60.4 ± 5.8 47.4 ± 5.7 † 50.0 ± 6.7 28.1 ± 5.8 * 
Values are means ± SD.  BMI, body mass index; TG, triglycerides; TC, total 
cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; 
SBP, systolic blood pressure; DBP, diastolic blood pressure, VO2 max, maximal 


























Figure 1.  Between-group comparisons showing influence of age and long-term 
exercise training on plasma levels of ox-LDL.  Values are means ± SE.  Data with 
















































Figure 2.  Main effects of age (A) and long-term exercise training (B) on plasma ox-


















































Figure 3A-B.  Significant relationships (P < 0.05) across all subjects between plasma 
levels of ox-LDL and the conventional CVD risk factors LDL cholesterol (A) and ox-

















































r = - 0.467
P = 0.003
 
Figure 3C-D.  Significant relationships (P < 0.05) across all subjects between plasma 
levels of ox-LDL and the conventional CVD risk factors total cholesterol to HDL 





























Figure 4.  Between-group comparisons showing influence of age and long-term 
exercise training on plasma levels of nitrotyrosine.  Values are means ± SE.  Data 

















































Figure 5.  Main effects of age (A) and long-term exercise training (B) on plasma 































Figure 6.  Significant relationship (P < 0.05) across all subjects between plasma 




























Figure 7.  Between-group comparisons showing influence of age and long-term 
exercise training on plasma levels of MPO.  Values are means ± SE.  Data with like 







































Figure 8.  Main effects of age (A) and long-term exercise training (B) on plasma 



























r = - 0.348
P = 0.035
 
Figure 9.  Significant relationship (P < 0.05) across all subjects between plasma MPO 






















Figure 10.  Between-group comparisons showing influence of age and long-term 
exercise training on plasma levels of NOx.  Values are means ± SE.  Data with like 
































Figure 11.  Main effects of age (A) and long-term exercise training (B) on plasma 























































Figure 12.  Significant relationships (P < 0.05) across all subjects between plasma 
NOx levels and VO2 max (A) and the conventional CVD risk factor total cholesterol 






















r = - 0.64
P = 0.008
 
Figure 13.  Significant relationship (P < 0.05) between plasma ox-LDL levels and 

















































Figure 14.  Significant relationship (P < 0.05) between plasma ox-LDL levels and 
























































Figure 15.  Significant relationships (P < 0.05) between plasma ox-LDL levels and 




























Figure 16.  Significant relationship (P < 0.05) between plasma MPO levels and ox-






The results of this study suggest that plasma oxidative stress levels are 
affected by long-term exercise training and age, but not consistently in the 
hypothesized direction.  In line with the presented hypotheses, ox-LDL levels did 
show a trend toward being lower with chronic exercise, with young and older active 
groups having significantly lower ox-LDL levels than young inactive individuals.  In 
addition, a main effect of age was reported in nitrotyrosine, with older individuals 
showing significantly elevated plasma nitrotyrosine levels compared to young 
subjects.  However, MPO levels were not reduced and NOx levels were not elevated 
in the chronic exercisers compared to their inactive peers, and older inactive 
individuals displayed the lowest MPO and the highest NOx levels.  The study also 
found that plasma NOx levels were not related to plasma oxidative stress levels.  
However, plasma oxidative stress levels, particularly ox-LDL levels, were related to 
various conventional CVD risk factors.  The relationships between oxidative stress 
markers and other CVD risk factors suggest that, at the very least, plasma oxidative 
stress levels may serve as indicators of CVD risk.  Plasma ox-LDL levels appear to be 
particularly attractive as potential markers of CVD risk, as the findings indicate that 
decreases in ox-LDL levels with chronic exercise could potentially explain some of 
the CVD risk reduction that occurs with regular exercise.  However, the lack of 
association between plasma oxidative stress and NOx levels does not support the 
hypothesis that reductions in NO bioavailability could explain how elevations in 




Effects of Age and Activity Level on Oxidative Stress Markers 
One of the hypotheses that has been put forth to explain aging has postulated 
that the loss of functional capacity during senescence can be explained by the 
irreversible accumulation of molecular oxidative damage (62).  Therefore, one would 
expect older individuals to have higher levels of oxidative stress than young 
individuals.  In the present study, however, only nitrotyrosine levels were elevated in 
the older subjects compared to the young subjects.  The findings suggest that plasma 
ox-LDL and MPO do not respond to age the same way that nitrotyrosine does.  Thus, 
perhaps not all of the selected oxidative stress markers contribute to the larger 
increase in oxidative damage that has been hypothesized to occur with age.  However, 
this study appears to be the first to compare the plasma levels of the selected 
oxidative stress markers across age groups, so it is difficult to make definitive 
conclusions about how the chosen oxidative stress biomarkers are affected by age. 
One alternative explanation for why the present study did not consistently 
show elevated oxidative stress levels in older groups is the unique nature of the study 
population.  All of the subjects studied were healthy individuals.  In contrast, most 
previous studies have compared ox-LDL, nitrotyrosine, and MPO levels in CVD 
patients to those in healthy controls, finding elevated oxidative stress levels with the 
onset and progression of the disease (21, 61, 69, 71).  Given the good health of the 
present study’s subjects, perhaps it is not surprising that plasma ox-LDL and MPO 
did not show age-related changes.  A previous study suggested that plasma ox-LDL 
levels are quite low in healthy people (24).  The present findings support this, as the 




(67.0 U/L) are relatively low compared to a previous study that reported an average 
ox-LDL level of 110 U/L in the plasma of patients who subsequently suffered a CVD 
event (39).  Thus, in the present study’s population of healthy subjects, age-related 
differences in plasma ox-LDL may be difficult to detect.  While there is currently no 
research in the literature on how age affects plasma MPO levels, one can speculate 
that the use of healthy subjects might also explain the lack of a main effect of age on 
MPO levels in the present study. 
When examining the effects of exercise on systemic levels of oxidative stress, 
one must consider the apparent contrasting effects of an acute exercise bout versus 
chronic exercise training.  A higher metabolic rate is required during an intense 
exercise bout, and it results in increased ROS generation during the bout and elevated 
oxidative stress levels after the bout (9).  However, some previous research has 
indicated that exercise training may reduce systemic levels of oxidative stress (15, 
45).  Thus, in the present study it was not surprising that a trend was observed linking 
active individuals to reduced plasma ox-LDL levels.  This trend is supported by 
exercise intervention studies that have found reduced plasma ox-LDL levels in older 
men and women following a high-intensity exercise intervention (10) and decreased 
serum ox-LDL concentration after exercise training in sedentary, healthy young men 
and women (13).  The lower plasma ox-LDL levels in active versus inactive subjects 
in the present study are thus consistent with other results reported in the literature. 
However, the present study demonstrated no such reduction in nitrotyrosine or 
MPO levels in the chronic exercise groups.  This finding was somewhat unexpected, 




exercise intervention in older subjects (15).  Another study reported a decline in 
serum MPO levels with a 12-week endurance training intervention in adult subjects 
with elevated CVD risk (56).  Although the present nitrotyrosine and MPO results do 
not agree with these previously reported findings, they are not without precedent.  
The effect of training on systemic levels of oxidative stress is still under investigation, 
and at least one human study concluded that older adults who exercise regularly have 
higher levels of oxidative stress than their sedentary peers (40).  The overall scarcity 
of information in the literature on changes in plasma ox-LDL, nitrotyrosine, and MPO 
levels with exercise training prevents definitive conclusions from being drawn on 
how chronic exercise affects systemic levels of oxidative stress. 
In addition, the present findings that nitrotyrosine and MPO levels were not 
reduced in active individuals compared to their inactive counterparts could be a result 
of the unique features of this particular study.  First of all, the present study examined 
the effects of long-term exercise training on oxidative stress levels, while all the 
previous studies have focused on the effects of short-term training.  The older 
subjects in the present study had exercised regularly for over thirty years, and the 
young subjects for over three years, and these training durations are vastly different 
from the typical twelve- to sixteen-week training intervention.  The beneficial effects 
of short-term training on plasma oxidative stress levels may disappear with continued 
training.  This would explain how the effects of long-term training on circulating 
biomarkers of oxidative stress could differ from the effects of short-term training. 
The second unique feature of the present study is the nature of the inactive 




issues and appeared to suffer no negative consequences from their years of physical 
inactivity.  Despite their sedentary lifestyles, the young inactive subjects had body 
weights, BMI values, body compositions, blood pressures, and blood chemistry 
profiles that were no different from their active peers who had been exercising 
regularly for over three years.  The older inactive subjects had body weights, BMI 
values, and blood pressures that were not statistically different from their active peers 
who had been exercising regularly for over thirty years.  This makes the individuals 
in both the young and older inactive groups quite exceptional.  The inactive subjects 
may share some genetic advantage that has allowed them to avoid many of the 
physical consequences typically associated with inactivity.  In the same way that the 
inactive subjects avoided obesity and hypertension, two negative consequences one 
would expect to occur with many years of inactivity, the inactive subjects in the 
present study may also have avoided higher oxidative stress levels.  This could 
explain why nitrotyrosine and MPO levels were not reduced in the long-term exercise 
training groups compared to the inactive groups. 
NOx Levels with Age, Activity Level, and Oxidative Stress 
 The present study found no main effects of age or activity level on plasma 
NOx levels.  These results contrast with previous research that indicates that NOx 
levels decline with age, resulting in impaired endothelium-dependent vasodilation 
that can be reversed with exercise training (12).  Other studies have also found that 
short-term aerobic exercise training increases plasma NOx concentration in healthy 
young individuals (36).  However, the responses to longer-term training (≥ 16 weeks) 




exercise training failed to result in any improvements in plasma NOx levels (5).  
Given the extremely long duration of training in the present study, the lack of 
association between activity level and plasma NOx levels is less surprising.  
The present study also found no relationships between plasma NOx levels and 
plasma ox-LDL, nitrotyrosine, or MPO levels.  These findings seem to contrast with 
previous research that has linked increases in oxidative stress to endothelial 
dysfunction (64).  However, the present study’s plasma NOx measurement is an 
assessment of NO bioavailability as opposed to a measurement of endothelial 
function.  Some functional test, such as forearm blood flow in response to reactive 
hyperemia or vasodilation in response to the infusion of an agonist, is needed to 
assess endothelial health.  Therefore, the present study’s finding that the older 
inactive group had significantly higher plasma NOx levels than either the older or 
young active groups does not mean that the older inactive group had the best 
endothelial function.  The only conclusion that can be drawn is that the older inactive 
group had the highest NO bioavailability.  Although a reduction in NO bioavailability 
is one of the mechanisms thought to cause endothelial dysfunction (5), impairments 
in endothelial function can occur without decreases in NOx levels.  For example, an 
earlier study found that atherosclerotic rabbits had higher plasma NO levels, as 
determined by quantifying nitrosyl compounds in blood, but impaired endothelium-
dependent vasodilation, compared to control rabbits (42).  Thus, plasma NOx levels 
are not necessarily directly related to endothelial function, and the present study only 





However, the lack of association between NO bioavailability and plasma 
oxidative stress levels in the present study is still surprising.  Previous research has 
shown that ox-LDL reduces NO bioavailability by reacting with NO to inactivate it 
and by stimulating the release of NO scavengers (28).  Elevated levels of 
nitrotyrosine have previously been associated with increased NO consumption and 
inhibited NO synthesis (7).  MPO has previously been shown to decrease NO levels 
by inhibiting and uncoupling NOS, and consuming NO (48).  A possible explanation 
for why the present study failed to uncover any associations between plasma ox-LDL, 
nitrotyrosine, and MPO levels and plasma NOx levels has already been discussed.  In 
a few words, the particularly long duration of training undertaken by the active 
subjects in this study may have resulted in different effects on plasma NOx levels 
than a short-term intervention.  The previously reported finding that plasma NOx 
levels do not improve with longer-term exercise training (5) suggests that any 
relationship between oxidative stress levels and NO bioavailability that occurs with 
short-term training may disappear with continued training.  
The present study also found significantly higher plasma NOx levels in the 
older inactive subjects than either the older active or young active groups.  There are 
several possible explanations for this surprising finding.  First of all, the elevated NO 
bioavailability in the older inactive subjects may be the result of the partial 
uncoupling of endothelial nitric oxide synthase (eNOS) with age and inactivity.  
When eNOS is fully uncoupled, usually due to the absence of the substrate L-arginine 
or the reduced availability of the cofactor BH4, the ROS superoxide and hydrogen 




eNOS produces superoxide and NO (7).  If old age or inactivity triggered the partial 
uncoupling of eNOS, the result would be runaway NO production.  Because NO is a 
free radical, unchecked NO production could be deleterious.  Therefore, the elevated 
NO bioavailability in the older inactive group could reflect a potentially harmful 
increase in NO production by the vascular endothelium. 
 Another possible explanation for the present study’s finding that the highest 
NOx levels occurred in the older inactive group is that the excess NO is being 
produced by some source other than the vascular endothelium.  Endothelial cells 
constitutively produce the NO that plays a role in vasodilation via eNOS (43).  
However, larger quantities of NO are produced in macrophages by inducible NOS 
(iNOS) in response to inflammatory stimuli (18).  Advanced age and inactivity may 
activate inflammatory pathways that result in increases in plasma NO via iNOS.  
Instead of improving endothelial health, the NO produced in response to 
inflammation has proatherogenic effects, oxidizing lipoproteins and promoting 
endothelial dysfunction (3).  Thus, the synthesis of NO by eNOS may be impaired 
with age or inactivity, but plasma NOx levels may actually increase due to the 
production of NO by inflammatory cells.  This would also explain how oxidative 
stress, which is known to activate the inflammatory response, might not be linked to 
reduced plasma NOx levels. 
Relationships between Oxidative Stress and Conventional CVD Risk Factors 
The present study found several significant relationships between oxidative 
stress levels, particularly ox-LDL, and conventional CVD risk factors.  Across all 




ratio of ox-LDL to LDL cholesterol, and the ratio of total to HDL cholesterol.  In 
addition, plasma ox-LDL was negatively correlated with HDL cholesterol.  These 
relationships between ox-LDL and blood lipid profiles are not unexpected or 
unprecedented.  First, ox-LDL molecules are formed by the oxidative modification of 
native LDL, so any increase in LDL is likely to be associated with an increase in ox-
LDL.  A significant positive association between ox-LDL and LDL cholesterol has 
been reported previously (22).  In addition, the negative association between ox-LDL 
and HDL levels fits with evidence suggesting that HDL molecules are 
atheroprotective in part because they inhibit LDL oxidation (41).  Indeed, a previous 
study supports the present finding that plasma ox-LDL levels are inversely correlated 
with HDL cholesterol levels (21).   
Fitting the observed relationship between ox-LDL and blood chemistry, ox-
LDL levels were also positively correlated with total cholesterol and triglycerides in 
the older subjects.  These findings are supported by previous research that has shown 
that hypercholesterolemia and dyslipidemia are strong independent predictors of 
plasma ox-LDL levels (20).  Also within the older subjects, ox-LDL levels were 
positively correlated with Framingham risk score and percentage, suggesting that ox-
LDL could have predictive value for CVD.  These results are supported by a study 
that found that plasma ox-LDL levels were predictive of future CVD events, and they 
were stronger predictors than the conventional lipoprotein profile, in apparently 
healthy men (39).  Thus, many of the ox-LDL correlations reported in the present 




Within inactive subjects, a positive relationship was observed between plasma 
MPO levels and the ratio of ox-LDL to LDL cholesterol.  Previous research has 
indicated that MPO can convert native LDL to ox-LDL (11).  In addition, one of the 
secondary oxidation products generated by MPO, nitrogen dioxide, has been reported 
to promote ox-LDL formation (6).  Thus, one would expect an increase in MPO to 
lead to an increase in ox-LDL formation, resulting in the increased ox-LDL to LDL 
ratio reported in the present study. 
Limitations 
 The present study is limited by the cross-sectional design and the relatively 
small sample size.  However, there was sufficient power to detect the differences 
indicated.  In addition, because the plasma ox-LDL levels in older and young subjects 
were measured separately, the comparisons across age groups for ox-LDL are less 
convincing.  Also, the use of plasma measurements may not be the best way to assess 
oxidative stress, as the systemic nature of these measurements means that they may 
not reflect the levels of oxidative stress present locally within every tissue.  However, 
there is substantial evidence to suggest that the plasma levels of the selected oxidative 
stress biomarkers do have clinical significance (4, 20-23, 39, 50, 61, 63, 66, 71).  In 
addition, the plasma markers of oxidative stress measured in the present study, 
although chosen because of their prevalence in previous research, may have left out 
other important plasma measurements such as malondialdehyde (MDA) or 
thiobarbituric acid reaction substances (TBARS). 
 Finally, the measurements of plasma ox-LDL, nitrotyrosine, and MPO levels 




construction of standard curves for each assay act as checks to make sure the values 
measured are accurate, but one must accept that the assay kits measure what they 
purport to measure.  The validity of any ELISA depends on the specificity of the 
primary antibody for the molecule of interest.  The researcher must accept that the 
antibodies provided in the kits by the manufacturers are binding the molecules of 






 The findings of the present study suggest that age and chronic exercise 
training do modify circulating biomarkers of oxidative stress.  While the effects of 
age and long-term exercise training on plasma markers of oxidative stress were not 
consistently in the hypothesized direction, there was evidence that a sedentary 
lifestyle may contribute to elevated ox-LDL levels and that nitrotyrosine levels may 
increase with age.  In addition, the results did not show a link between plasma 
oxidative stress and plasma NOx levels, underscoring the need for further research to 
elucidate how elevations in oxidative stress levels contribute to increases in CVD 
risk.  Additionally, the many associations between plasma oxidative stress levels and 
conventional CVD risk factors suggest that plasma oxidative stress may serve as a 
marker of CVD.  Future research may even show that oxidative stress plays a role in 
the pathogenesis of atherosclerosis.  The present study also indicates that reductions 
in plasma oxidative stress, particularly plasma ox-LDL, may explain some of the 
observed reduction in CVD risk with exercise training.  This sets the stage for future 
research to determine how the training-induced reduction in oxidative stress levels 
could help prevent CVD.  And finally, while more investigation is needed, the present 
results suggest that adding a measure of plasma oxidative stress to the conventional 






Review of Literature 
 
Cardiovascular Disease (CVD) 
CVD and Atherosclerosis 
 Cardiovascular diseases include high blood pressure, coronary heart disease, 
stroke, and heart failure.  Collectively, these diseases of the heart and vasculature are 
the number one cause of mortality in the developed world.  The process underlying 
the development of CVD is atherosclerosis.  The atherosclerotic process is 
characterized by the narrowing of arteries due to plaque buildup.  In addition to 
impeding blood flow, the plaques can rupture, compromising the flow of oxygen to 
critical organs.  The response to injury hypothesis of atherosclerosis says that the 
process begins when the endothelial layer, which is the semi-permeable barrier 
between the blood and the arterial wall, is injured.  While the exact sequence of 
events is still being studied, the injury to the vessel wall is believed to trigger a 
change in endothelial permeability that allows LDL cholesterol molecules to enter the 
intima where they undergo chemical changes.  Once modified, LDL molecules first 
attract monocytes, forming foam cells, and then recruit smooth muscle cells, forming 
fatty streaks.  The buildup of smooth muscle cells and the subsequent development of 
a connective tissue network results in a fibrous plaque that begins to narrow the 
artery.  When the plaque is disrupted, it may block blood flow or trigger more 




outline of the atherosclerotic process is commonly used as the foundation for further 
studies attempting to provide a more complete picture of the process. 
Conventional Risk Factors 
 In the last 50 years, extensive research has identified several factors that 
independently and significantly increase a person’s risk for developing CVD.  These 
intensely-studied risk factors include gender, heredity, smoking status, high 
cholesterol, hypertension, obesity, and diabetes.  Two of the conventional risk factors 
particularly relevant to this study are age and physical inactivity. 
 The increase in CVD risk with increasing age is striking.  An average 
American male aged 30-34 has a 3% risk of developing CVD over a ten-year period, 
while his ten-year risk jumps to 21% when he is 60-64 years old (69). 
 In addition, studies have repeatedly linked physical inactivity to unfavorable 
CVD risk factor profiles, including elevated LDL levels and blood pressure, reduced 
HDL levels, and increased risk of diabetes and obesity (17).  Also well-established is 
the reduction in CVD risk that occurs with exercise training.  In previously sedentary 
individuals, it is generally estimated that exercise training reduces LDL cholesterol by 
10 mg/dL, increases HDL cholesterol by 5 mg/dL, decreases systolic blood pressure 
by 10 mm Hg, and decreases diastolic blood pressure by 8 mm Hg.  In addition, only 
7 days of exercise training has been found to improve glucose tolerance and decrease 
insulin resistance in subjects with mild Type II diabetes (58).  The importance of 
physical inactivity as a risk factor for CVD is underscored by a meta-analysis that 
found a relative risk of death from CVD of 1.9 for inactive individuals compared to 




Novel Risk Factors 
 The conventional risk factors above have long been considered in estimating 
an individual’s CVD risk.  However, in the late 1990s, a growing number of 
researchers began to question the degree to which conventional risk factors accounted 
for a person’s CVD risk.  Several studies concluded that conventional CVD risk 
factors might explain only 50% of CVD cases (16).  In addition, the exercise training-
induced reductions in CVD risk could be only partially explained by improvements in 
conventional risk factors.  For example, Mora and colleagues associated higher levels 
of physical activity with fewer CVD events and found that differences in 
conventional risk factors could explain only 59% of that inverse relationship (44).  
The implication that other factors must play a significant role in the development of 
CVD has not been accepted without debate.  Research has emerged to bolster the 
earlier claims that conventional risk factors account for far more than 50% of an 
individual’s CVD risk (31). 
Although the question is not yet settled, the ongoing debate has led to a 
growing body of research attempting to identify additional CVD risk factors that 
might help provide a more complete picture of a person’s CVD risk.  Much of the 
attention has focused on emerging risk factors in the areas of oxidative stress, 
inflammation, and endothelial dysfunction.  Potential novel CVD risk factors in the 
area of oxidative stress include plasma levels of oxidized LDL, nitrotyrosine, and 
myeloperoxidase.  Because of the many physiological and biochemical links among 
oxidative stress, inflammation, and endothelial dysfunction in the pathology of 





 Energy is produced in mammalian cells by reducing oxygen to water during 
aerobic respiration.  These reduction-oxidation reactions produce reactive oxygen 
species (ROS) as intermediates, and these by-products influence a variety of cellular 
activities in both normal and pathological conditions (47).  ROS have been shown to 
play important roles in cell signaling, vascular growth and differentiation, cell 
apoptosis, and platelet aggregation (14).  To properly execute these roles, ROS 
production must be carefully modulated and a steady-state balance must be 
maintained between the levels of oxidants and antioxidants.  When this delicate 
balance is disrupted and excess ROS results, the body experiences “oxidative stress” 
as the highly reactive ROS interact with lipids, proteins, and DNA to cause cellular 
damage (47).  In addition to cell damage, research suggests that oxidative stress can 
contribute to the development of various pathologies including aging, dementia, and 
atherosclerosis (47). 
ROS and RNS 
ROS can be divided into two categories: nonradicals and free radicals (64).  
Important nonradicals in oxidative stress pathways include hydrogen peroxide (H2O2) 
and hypochlorous acid (HOCl).  Free radicals are highly reactive because they have at 
least one unpaired electron.  When two free radicals meet, they will usually join their 
unpaired electrons to form a covalent bond, resulting in a nonradical product.  An 
example of this is the reaction between the free radicals superoxide and nitric oxide to 
form the nonradical product peroxynitrite: 




A free radical can also react with nonradical molecules, either by abstracting a 
hydrogen atom from the nonradical or adding to it (64).  Lipids, proteins, and nucleic 
acids are all examples of nonradicals that are altered in reactions with free radicals 
(47).  Because the products of these reactions are free radicals, ROS production is 
amplified, potentially leading to oxidative stress. 
In addition to ROS, reactive nitrogen species (RNS) are often referred to as 
oxidants because of their tendency to remove electrons.  The oxidative stress and 
resulting cell damage associated with ROS can be equated to the nitrosative stress 
caused by RNS, and in many studies, including this one, the term “oxidative stress” is 
used to describe the impact of both excess ROS and RNS.  In addition, this paper may 
at times refer to “nitro-oxidative stress” in an attempt to encompass the damage 
caused by both of these processes. 
Sources of ROS 
 The major intracellular source of ROS is the mitochondrial electron transport 
chain, which produces superoxide as a by-product (29).  The ROS in blood vessels 
have several other sources, including NADPH oxidase, xanthine oxidase, eNOS, 
lipoxygenase, and myeloperoxidase (64).   
The NADPH oxidase enzyme complex, present in many cells including 
vascular smooth muscle cells and endothelial cells, catalyzes the reduction of 
molecular oxygen to generate superoxide.  Xanthine oxidase catalyzes the oxidation 
of xanthine to uric acid, generating superoxide in the process.  Endothelial nitric 
oxide synthase (eNOS) is responsible for the oxidation of L-arginine to nitric oxide 




arginine, resulting in superoxide formation (64).  Lipoxygenases catalyze the 
oxidation of polyunsaturated fatty acids.  Myeloperoxidase (MPO) is a heme-
containing enzyme secreted from macrophages and neutrophils.  MPO catalyzes the 
formation of the nonradical oxidant HOCl in the following reaction: 
H2O2 + Cl- + H+ → HOCl + H2O 
HOCl can oxidize nitrite to the nonradical oxidant nitryl chloride and the radical 
nitrogen dioxide, both of which promote nitrotyrosine production (64). 
 By producing various oxidants that can alter lipids and proteins, the above 
enzymes can contribute to oxidative stress in certain pathological states. 
CVD and Nitro-Oxidative Stress 
 As discussed previously, atherosclerosis develops in response to an 
endothelial injury or dysfunction which changes the permeability of the blood vessel 
wall (59).  The resulting movement of LDL molecules into the subendothelial space, 
where they are subject to uptake by macrophages, results in foam cell formation.  
These foam cells become fatty streaks and are covered by fibrous plaques and, 
ultimately, an atherosclerotic lesion, after smooth muscle cells, additional lipids, 
leukocytes, and platelets are attracted and bound to the site.  Recent research indicates 
that the oxidative stress resulting from ROS and RNS plays a crucial role in CVD.  
The proposed role of oxidative stress in atherosclerosis has been termed the oxidative 
modification hypothesis (64).  According to this hypothesis, oxidized molecules play 
an important role in atherosclerosis both by embedding in the vascular wall and 
promoting plaque formation and by interacting with inflammatory and endothelial 




Markers of Nitro-Oxidative Stress 
 One way to evaluate the amount of cell damage that is occurring due to ROS 
and RNS is to measure products of oxidative processes that can be found in human 
plasma.  Ox-LDL and nitrotyrosine are two such products that can serve as indicators 
of the body’s level of nitro-oxidative stress.  In addition, the presence of enzymes that 
catalyze reactions producing oxidants can provide a measure of excess ROS in the 
body.  MPO, a source of oxidants, is an example of such an enzyme that can be found 
and measured in human plasma.  
Oxidized LDL (Ox-LDL) 
 The term ox-LDL does not define a particular molecule, referring instead to a 
non-homogeneous population of modified forms of LDL.  Circulating levels of ox-
LDL are the result of oxidation in the arterial wall, most likely by MPO, 
lipoxygenases, or RNS such as peroxynitrite (41).  The oxidation of LDL begins with 
the loss of LDL’s endogenous antioxidants, followed by the conversion of most 
polyunsaturated fatty acids to hydroperoxides that then react with lysine residues of 
apolipoprotein B-100 (64).  LDL peroxidation leaves the lipoprotein more negatively 
charged, resulting in a decreased affinity for the LDL receptor and an increased 
affinity for scavenger receptors in endothelial cells, smooth muscle cells, and 
macrophages (41).  The oxidative modification of LDL in the vascular wall is an 
important step in the initiation and progression of atherosclerosis because it is 
oxidized LDL, not native LDL, that is trapped by macrophages in the subendothelial 




smooth muscle cells, resulting in the formation of foam cells which can eventually 
develop into the fatty streaks characteristic of CVD (34). 
An important early step in atherosclerosis is the adhesion of monocytes and 
lymphocytes to the endothelium, and ox-LDL facilitates this by up-regulating the 
transcription of adhesion molecules like vascular cell adhesion molecule (30).  In 
addition to its effects on smooth muscle cell migration mentioned above, ox-LDL 
also supports foam cell formation by promoting monocyte infiltration into the 
subendothelial space, encouraging monocyte proliferation and differentiation into 
macrophages, and hindering the ability of resident macrophages to leave the intima 
(64).  Interestingly, one way that HDL cholesterol prevents atherosclerosis is by 
inhibiting LDL oxidation and by reversing the enhanced monocyte recruitment 
triggered by ox-LDL (41). 
Ox-LDL is also linked to endothelial dysfunction because it can reduce NO 
bioavailability and lead to vascular remodeling.  Ox-LDL reduces NO levels directly, 
by reacting with NO to inactivate it, and indirectly, by stimulating the release of NO 
scavengers (28).  Ox-LDL may also induce vasoconstriction by inhibiting NO 
production and stimulating endothelin expression, and a reduction in the arterial 
lumen occurs with the accumulation of foam cells and the necrosis and apoptosis 
induced by ox-LDL (41).  Collectively, the reduced NO bioavailability and the 
thickening of the intimal layer impair the function of the endothelium. 
Ox-LDL is also associated with increased thrombosis because ox-LDL 
stimulates platelet adhesion and aggregation, enhances the endothelium’s pro-




plays a role in foam cell formation, plaque rupture, endothelial dysfunction, vascular 
remodeling, and thrombosis. 
CVD and Plasma Ox-LDL Levels 
 
As mentioned previously, research has shown that it is ox-LDL, and not native 
LDL, that makes up aortic lesions (51).  Although atherosclerotic lesions are enriched 
with ox-LDL, the plasma of healthy persons typically has very low levels of ox-LDL 
(24).  However, an increase in plasma ox-LDL levels occurs in certain pathological 
conditions, including carotid artery atherosclerosis and acute myocardial infarction, 
when atherosclerotic lesions rupture and expose accumulated ox-LDL to the 
bloodstream (23). 
Further investigation has revealed that elevated levels of circulating ox-LDL 
are present not only during clinical manifestations of CVD, but also with the 
symptom-less onset and progression of the disease.  For example, plasma ox-LDL 
levels in clinically healthy men independently predict plaque occurrence in the 
carotid and femoral arteries and are related to intima-media thickness and levels of 
the inflammatory marker C-reactive protein (22).  In addition, studies have found 
increased plasma ox-LDL levels in people with coronary artery disease (21). 
Even before the onset of CVD, however, circulating ox-LDL levels have been 
shown to be a useful marker for identifying individuals with a high risk of developing 
the disease (20).  Mounting evidence suggests that plasma ox-LDL levels may 
contribute as much to the development of CVD and the risk of cardiac events as 
current conventional risk factors such as total cholesterol.  In one study of apparently 




were stronger predictors than the conventional lipoprotein profile (39).  Another study 
identified an elevated ratio of plasma ox-LDL relative to total cholesterol as a 
possible indicator of increased acute myocardial infarction risk (50).  While more 
research is needed to definitively establish ox-LDL as a CVD risk factor, the 
literature points to a strong link between plasma ox-LDL levels and the initiation, 
development, and clinical outcomes of CVD. 
Nitrotyrosine 
 The formation of 3-nitrotyrosine in proteins results from the nitration of 
tyrosine, making it an indicator of nitro-oxidative stress.  RNS including nitryl 
chloride, nitrogen dioxide, and peroxynitrite can mediate 3-nitrotyrosine production.  
As mentioned previously, nitryl chloride and nitrogen dioxide are the ultimate 
products of the MPO-catalyzed formation of the oxidant hypochlorous acid.  
Peroxynitrite (ONOO-), a powerful oxidant, results from the reaction of the free 
radicals nitric oxide and superoxide. 
Superoxide anions are generated by components of atherosclerotic lesions 
including endothelial cells, smooth muscle cells, and macrophages, suggesting that 
peroxynitrite production occurs in the vascular wall (33).  While antioxidant defenses 
appear to protect NO from superoxide scavenging in healthy individuals, diseases like 
atherosclerosis may partially uncouple eNOS and result in increased generation of 
both NO and superoxide, leading to peroxynitrite formation (7).  Peroxynitrite 
promotes atherosclerosis by oxidizing lipids, proteins, and DNA, and contributing to 




3-nitrotryosine production they mediate serves as a stable marker of nitro-oxidative 
stress. 
As indicated previously, peroxynitrite is one of the molecules responsible for 
LDL oxidation.  After in vitro studies showed that 3-nitrotyrosine was a highly 
specific marker for LDL oxidized by peroxynitrite, an in vivo study found that 
nitrotyrosine levels were 90-fold higher in LDL isolated from atherosclerotic lesions 
than in native LDL isolated from the plasma of healthy individuals (33).  Thus 
nitrotyrosine levels reflect the RNS production and subsequent oxidative 
modifications occurring in the vascular wall. 
Nitrotyrosine is associated with endothelial dysfunction because the RNS that 
lead to its formation reduce NO bioavailability.  Peroxynitrite production consumes 
NO, and once formed, peroxynitrite may uncouple eNOS by oxidizing 
tetrahydrobiopterin (BH4), a cofactor necessary for NO synthesis (7).  Any 
uncoupling of eNOS promotes endothelial dysfunction by decreasing NO production 
and leads to oxidative stress by generating superoxide.  In addition, the depletion of 
important plasma antioxidants and nitration of proteins that occur because of 
peroxynitrite lead to endothelium damage that induces thickening of the intima in the 
arterial wall and impairs vasodilation (65).  Nitrotyrosine production clearly has 
important consequences for endothelial function, and thus has been linked to CVD. 
CVD and Plasma Nitrotyrosine Levels 
 Research continues to examine nitrotyrosine as both a marker of the nitro-
oxidative stress present in pathological conditions and a part of the molecular basis of 




increase significantly in disease states including inflammatory and cardiovascular 
disorders (63).  For example, patients with celiac disease displayed elevated plasma 
nitrotyrosine levels compared to controls (66).  Patients with established coronary 
artery disease had plasma nitrotyrosine levels almost twice as high as their healthy 
peers.  These nitrotyrosine levels were significantly reduced with statin therapy, 
demonstrating the ability of statins to inhibit superoxide formation (61).  In a study of 
clinical CVD patients, atherosclerotic blood vessels had significantly elevated tissue 
levels of nitrotyrosine when compared to control vessels (65).  Thus, there is 
substantial evidence that elevated nitrotyrosine levels accompany many disease states. 
Research also supports the hypothesis that RNS play an important role in 
CVD by promoting lipid oxidation.  In human coronary arteries, the endothelium, 
foamy macrophages, and inflammatory cells associated with atheroma all display 
signs of extensive nitration (1).  Not surprisingly, an analysis of protein oxidation 
products in atherosclerotic lesions has revealed enriched nitrotyrosine levels, 
indicating that nitration induces lipoprotein aggregation (18).  So in addition to 
serving as a strong indicator of nitro-oxidative stress in various disease states, 
nitrotyrosine formation may be involved in the pathogenesis of atherosclerosis. 
Myeloperoxidase (MPO) 
 By catalyzing the production of ROS and RNS, MPO contributes to nitro-
oxidative stress.  The enzyme MPO is the single most abundant protein in neutrophils 
and is also present in monocytes, two types of white blood cells that ingest bacteria 
and damaged or dead cells by phagocytosis (52).  Collectively called phagocytes, 




activated endothelial cells and macrophages express cytokines that attract phagocytes 
to sites of acute inflammation in tissues.  The neutrophils and monocytes migrate 
toward the inflammatory site by chemotaxis, and once they reach it they ingest the 
pathogen or damaged cells and secrete MPO.  After being released, active MPO can 
adhere to endothelial cells, leukocytes, and lipoproteins (8). 
As described earlier, MPO catalyzes the production of hypochlorous acid, a 
cytotoxic oxidant: 
H2O2 + Cl- + H+ → HOCl + H2O 
In addition to its role in killing engulfed bacteria, hypochlorous acid may also injure 
normal tissue with its protein-destroying capabilities (11).  Once hypochlorous acid is 
produced, it can lead to the formation of other secondary oxidation products including 
nitryl chloride and nitrogen dioxide.  These MPO-generated oxidants can bind HDL 
cholesterol in atherosclerotic plaques, rendering the “good” cholesterol molecules 
dysfunctional (49).  So not only does MPO lead to ROS and RNS production and 
subsequent nitro-oxidative stress, but it also inhibits some atheroprotective 
mechanisms. 
MPO also seems to promote endothelial dysfunction by limiting NO 
bioavailability through several mechanisms.  MPO inhibits and uncouples NOS, 
reducing NO synthesis, and MPO and its secondary oxidation products consume NO 
(48).  Evidence that MPO impairs endothelium function includes a human study that 
found an inverse relationship between serum MPO levels and NO-dependent 





 Research also indicates that MPO activity is an important pathway for the 
conversion of native LDL to its pro-atherogenic form ox-LDL.  The enzyme’s role in 
the oxidative modification of LDL was first suggested by the presence of active MPO 
in human vascular lesions (11).  MPO seems to play a role in lipoprotein oxidation 
because of its production of hypochlorous acid and other secondary oxidation 
products.  LDL molecules that have been modified by hypochlorous acid have been 
shown to stimulate foam cell formation, increase leukocyte adherence and migration 
into blood vessels, boost leukocyte ROS production, and encourage the chemotactic 
activity of neutrophils (64).  This MPO-induced migration and aggregation of various 
leukocytes could contribute to plaque disruption.  And similar to hypochlorous acid, 
other MPO-generated oxidants like nitrogen dioxide have been shown to promote ox-
LDL formation (6).  Thus, MPO activity is linked to both the oxidative modification 
of LDL and the activation of the inflammatory response which are essential to the 
pathogenesis of CVD. 
CVD and Plasma MPO Levels 
Plasma MPO levels have been shown to have prognostic value for CVD.  
Patients with coronary artery disease had elevated blood and leukocyte MPO levels 
compared to controls, suggesting the enzyme’s role as an inflammatory marker of 
CVD (71).  In patients presenting to the hospital with chest pain, plasma levels of 
MPO independently predicted a person’s risk of myocardial infarction and other 
future major adverse cardiac events in the ensuing six months (4).  The evidence 




However, further research suggests that MPO is more than just a marker of 
pathological conditions.  MPO also appears to be a causative factor in the disease 
states.  Both MPO and MPO-generated oxidants have been implicated as participants 
in tissue injury in inflammatory conditions including kidney disease and asthma (48).  
In addition, people with partial and total MPO deficiency are less likely to develop 
CVD (32).  While more research is needed, MPO appears to play a role in 
atherosclerosis through pathways of nitro-oxidative stress, endothelial dysfunction, 
and inflammation. 
Effects of Exercise Training on Nitro-Oxidative Stress 
 As discussed previously, endurance exercise training has been repeatedly 
shown to decrease CVD risk by improving both conventional and novel risk factors.  
Although not studied extensively, evidence shows that exercise training reduces 
systemic oxidative stress (45).  However, an acute bout of vigorous exercise actually 
increases oxidative stress because the higher respiration rate required during intense 
exercise leads to the production of more free radicals (9).  The contrasting effects of 
exercise training and an acute exercise bout indicate that progressive adaptations 
occur with exercise.  The plasma oxidative stress induced with each exercise bout 
may stimulate the arterial antioxidant response, decrease basal oxidant production, 
and increase eNOS activity, resulting in the ultimate drop in oxidative stress with 
training (38).  However, much of the work supporting these mechanisms has been 
done in animal models.  The effect of training on the antioxidant-oxidant balance in 




In addition to the research on oxidative stress and exercise training, a few 
exercise intervention studies have examined changes in the identified nitro-oxidative 
stress markers with training.  Plasma ox-LDL levels were reduced with a high-
intensity exercise intervention in sedentary men and women over the age of 55 (10).  
In sedentary, healthy young men and women, exercise training increased endogenous 
antioxidant activity, decreased serum ox-LDL concentration, and increased LDL 
resistance to oxidation (13).  Other studies, using baseline levels of conjugated dienes 
extracted from LDL as an indicator of LDL oxidation, found that levels of these so-
called “mildly oxidized LDL” were reduced in young trained girls and older veteran 
athletes compared to controls, and after exercise training in previously sedentary 
middle-aged men and women (67). 
Even less research has been done on changes in nitrotyrosine and 
myeloperoxidase with training.  In subjects over the age of 65, plasma nitrotyrosine 
levels were decreased by 20% with a 16-week exercise intervention, and subsequent 
detraining abolished these adaptations (15).  Serum MPO levels declined 28% in 
adult subjects with elevated CVD risk after a 12-week endurance training intervention 
(56).  While these previous studies provide evidence that relatively short-term 
exercise training improves plasma levels of oxidative stress markers, little research 
has examined the effects of long-term exercise training.  In addition, while some have 
speculated about the mechanisms linking oxidative stress to inflammation and 






 Inflammation is emerging as a risk factor for CVD, with preliminary research 
finding that levels of inflammatory markers such as C-reactive protein (CRP) are 
predictive of CVD (57).  However, more relevant to the present paper is the 
intersection of oxidative stress and inflammation in the development of CVD.  
Research is still needed to determine whether the oxidative stress triggers the 
inflammatory response or the inflammation initiates atherosclerosis and promotes 
oxidative modification as a result.  But either way, these two emerging CVD risk 
factors are tightly linked. 
First of all, even when properly balanced with antioxidants, ROS and RNS 
play an important role in host defense and antimicrobial activity.  Their role in the 
immune response is evidenced by the association of impaired ROS/RNS production 
with susceptibility to bacterial or parasitic infection (64).  When excess ROS/RNS 
accumulates and oxidative modifications result, it is no surprise that inflammatory 
pathways are involved.  The positive relationship between levels of CRP and ox-LDL 
points to the interaction between inflammation and oxidation, and LDL oxidation has 
been found to trigger a state of chronic, low-level inflammation that leads to plaque 
development (20). 
During atherosclerosis, the inflammatory response leads to the recruitment 
and adherence of leukocytes and platelets to the sites of endothelial injury (64).  As 
discussed previously, ox-LDL facilitates this adhesion by up-regulating the 
transcription of various adhesion molecules (30).  Some leukocytes that aggregate at 




modifications.  In addition, leukocytes release proinflammatory cytokines which 
increase coagulation and cause an unfavorable lipid profile characterized by 
decreased HDL cholesterol and increased triglycerides (19).  Components of the 
inflammatory response are also responsible for macrophage and smooth muscle cell 
recruitment into the vascular wall, contributing to foam cell and fatty streak 
formation.  Thus, atherosclerosis can be thought of as a chronic inflammatory process 
whose pathogenesis is intimately linked to oxidative damage. 
Endothelial Dysfunction 
 Separating the arterial wall from flowing blood is the endothelium, a thin 
layer of cells that acts as a selectively-permeable barrier and plays a key role in 
regulating vascular function by releasing several autocrine and paracrine factors 
including nitric oxide (NO) (47).  NO is a vasodilator that has several antiatherogenic 
effects, including the regulation of blood pressure and vascular tone, and the 
inhibition of platelet aggregation, vascular smooth muscle cell proliferation, and 
leukocyte adhesion (46).  Many disease processes, including atherosclerosis, are 
characterized by a reduction in NO bioavailability.  The decline in NO bioactivity 
results in abnormal vascular homeostatic function, a condition called endothelial 
dysfunction. 
Nitric Oxide (NO) 
NO is a diffusible gas that is so rapidly scavenged that it has a half-life of only 
a few seconds (3).  While this short half-life makes measuring NO unfeasible, the 




Collectively called NOx, nitrite and nitrate concentrations serve as an indicator of NO 
production (53). 
 NO is synthesized in trace quantities by a reaction of oxygen, arginine, and 
NADPH that is catalyzed by nitric oxide synthase (NOS).  The NO that plays a role in 
vasodilation is constitutively produced in endothelial cells, platelets, and neutrophils 
by endothelial NOS (eNOS) in response to homeostatic stimuli (43).  However, larger 
quantities of NO are produced in macrophages by inducible NOS (iNOS) in response 
to inflammatory stimuli (18).  Instead of improving endothelial health, the NO 
produced in response to inflammation has proatherogenic effects, oxidizing 
lipoproteins and promoting endothelial dysfunction (3).  Thus, in addition to its 
relationship to oxidative stress, inflammation also plays a role in endothelial 
dysfunction. 
CVD and Endothelial Dysfunction 
 The link between endothelial dysfunction and CVD is well-established.  
Measures of endothelial function, such as endothelium-dependent vasodilation, have 
been shown to predict long-term CVD progression and future CVD events in patients 
with atherosclerosis (60).  The loss of endothelium-dependent vasodilation reflects an 
impairment in endothelium-derived NO bioactivity (47).  Thus, decreased NO 
bioavailability is indicative of endothelial dysfunction.  As outlined previously, ox-
LDL, nitrotyrosine, and MPO have all been linked to reduced NO bioavailability by 
either decreasing NO production, increasing NO scavenging, or uncoupling eNOS.  
Thus, excess ROS production and oxidative stress are associated with endothelial 




that triggers oxidative modifications or simply a result of oxidative stress is not 
known. 
Effects of Exercise Training on Endothelial Function 
Previous research has shown that exercise training can reverse age-related 
decrements in endothelium-dependent vasodilation and that active individuals have 
increased NO bioactivity compared to their sedentary peers (12).  In addition, plasma 
NOx levels have been found to increase with exercise training in various populations.  
Intense aerobic exercise training increased plasma NOx concentration in healthy 
young individuals (36).  In previously sedentary older women, three months of mild 
aerobic-endurance exercise significantly increased plasma NOx levels (37).  Evidence 
indicates that physical activity improves endothelial function and can increase NO 
bioavailability.  The apparent links between oxidative stress and endothelial 
dysfunction suggest that the changes in plasma levels of ox-LDL, nitrotyrosine, and 
MPO with exercise training are concomitant with changes in plasma NOx.  The 
present study will look simultaneously at the training-induced changes in oxidative 
stress markers and NO bioavailability to try to better understand the mechanisms 
underlying the improvements in CVD risk with training.  In addition, the study will 
extend recent findings relative to exercise and age effects on novel CVD risk factors.   
Summary 
 
 While conventional risk factors explain a significant portion of CVD risk, 
emerging factors like oxidative stress, inflammation and endothelial dysfunction 




stress markers that have been linked to atherosclerosis.  While the mechanisms by 
which oxidative stress promotes CVD are not yet fully understood, research suggests 
that oxidative modifications may impair endothelial function.  Endothelial 
dysfunction, characterized by reduced NO bioactivity, seems to promote the 
inflammatory response essential to atherosclerosis.  Thus, the intersection of 
oxidative stress, endothelial dysfunction, and inflammation pathways seems to be 
important in the disease process.  
Early evidence also suggests that exercise training may be able to reduce CVD 
risk in part by decreasing levels of oxidative stress.  The training-induced decline in 
oxidative stress may result in improved endothelial function, which in turn decreases 
an individual’s CVD risk.  Great progress has been made in understanding the 
pathogenesis of atherosclerosis and the effects of exercise training on CVD risk, but 
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